Deutsche Bank Ag\ Sesen Bio, Inc. Transaction History

Deutsche Bank Ag\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.38 - $0.89 $43,437 - $101,735	-114,309 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.58 - $0.86 $8,885 - $13,175	-15,320 Reduced 11.82%	114,309 $69,000
Q4 2021 Feb 11, 2022	SELL	$0.73 - $1.28 $543,635 - $953,223	-744,706 Reduced 85.17%	129,629 $106,000
Q3 2021 Nov 04, 2021	SELL	$0.77 - $4.91 $232,652 - $1.48 Million	-302,146 Reduced 25.68%	874,335 $693,000
Q2 2021 Aug 11, 2021	BUY	$2.18 - $4.66 $427,406 - $913,630	196,058 Added 20.0%	1,176,481 $5.44 Million
Q1 2021 May 13, 2021	BUY	$1.3 - $3.24 $1.24 Million - $3.09 Million	954,350 Added 3660.3%	980,423 $2.55 Million
Q3 2020 Nov 12, 2020	BUY	$0.67 - $1.4 $17,468 - $36,502	26,073 New	26,073 $37,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.51 $728 - $1,057	-700 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$0.95 - $2.46 $665 - $1,722	700 New	700 $1,000
Q4 2018 Feb 14, 2019	SELL	$0.96 - $2.04 $13,440 - $28,560	-14,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$1.54 - $2.38 $39,228 - $60,625	-25,473 Reduced 64.53%	14,000 $30,000
Q2 2018 Aug 14, 2018	BUY	$1.04 - $3.29 $41,051 - $129,866	39,473 New	39,473 $76,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.